New drug candidate B-OT passes first human safety check
NCT ID NCT07450833
First seen Mar 17, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This early-stage study tested a new drug called Benfo-Oxythiamine (B-OT) in 48 healthy male volunteers to see if it is safe and how the body processes it. Participants took the drug as capsules, either once or daily for a week, and were closely monitored in the clinic. The results will help decide if B-OT should move into future trials for infectious diseases and cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Diagnostics and Consultation Center (DCC) Convex EOOD
Sofia, Bulgaria
Conditions
Explore the condition pages connected to this study.